Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance

Opinion statement Cytogenetics and mutation identification in acute myeloid leukemia have allowed for more targeted therapy. Many therapies have been approved by the FDA in the last 3 years including gilteritinib and azacitidine but the overall survival has remained stagnant at 25%. The inability to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current treatment options in oncology 2021-09, Vol.22 (9), p.76-76, Article 76
Hauptverfasser:	Uddin, Rehan, Darwish, Noureldian H. E., Mousa, Shaker A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Antigens Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bioavailability Biomarkers, Tumor Bone marrow CD123 antigen Ceramidase Combined Modality Therapy - methods Cytogenetics Disease Susceptibility Drug resistance Drug Resistance, Neoplasm - genetics Gene Expression Regulation, Leukemic - drug effects Humans Immunotherapy Leukemia Leukemia (PH Wiernik Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - therapy Lymphocytes T Medicine Medicine & Public Health Molecular Targeted Therapy - adverse effects Molecular Targeted Therapy - methods Mutation Myeloid leukemia Nanomedicine Oncology Precision Medicine Remission Section Editor Stem cells Surface antigens Topical Collection on Leukemia Treatment Outcome Tumor Microenvironment - drug effects Tumor Microenvironment - genetics Tumor Microenvironment - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!